ME03805B - UPOTREBA KOMPOZICIJE KOlA OBUHVATA MIKROORGANIZME ZA POVEĆANJE INTESTINALNE PROIZVODNJE BUTERNE KISELINE, FOLNE KISELINE ILI NIACINA I/ILI SMANJENJE INTESTINALNE PROIZVODNJE ĆILIBARNE KISELINE - Google Patents
UPOTREBA KOMPOZICIJE KOlA OBUHVATA MIKROORGANIZME ZA POVEĆANJE INTESTINALNE PROIZVODNJE BUTERNE KISELINE, FOLNE KISELINE ILI NIACINA I/ILI SMANJENJE INTESTINALNE PROIZVODNJE ĆILIBARNE KISELINEInfo
- Publication number
- ME03805B ME03805B MEP-2020-143A MEP2020143A ME03805B ME 03805 B ME03805 B ME 03805B ME P2020143 A MEP2020143 A ME P2020143A ME 03805 B ME03805 B ME 03805B
- Authority
- ME
- Montenegro
- Prior art keywords
- composition
- use according
- acid
- bacterial strain
- intestinal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 9
- 230000000968 intestinal effect Effects 0.000 title claims 6
- 244000005700 microbiome Species 0.000 title claims 2
- 239000002253 acid Substances 0.000 title 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title 1
- 229960000304 folic acid Drugs 0.000 title 1
- 235000019152 folic acid Nutrition 0.000 title 1
- 239000011724 folic acid Substances 0.000 title 1
- 229960003512 nicotinic acid Drugs 0.000 title 1
- 235000001968 nicotinic acid Nutrition 0.000 title 1
- 239000011664 nicotinic acid Substances 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 claims 5
- 241000186605 Lactobacillus paracasei Species 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010013554 Diverticulum Diseases 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 235000013351 cheese Nutrition 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 235000013325 dietary fiber Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000015203 fruit juice Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000011573 trace mineral Substances 0.000 claims 1
- 235000013619 trace mineral Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 235000013618 yogurt Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (9)
1.Bakterijski soj Lactobacillus paracasei DG deponovan u Nacionalnoj zbirki kultura mikroorganizama instituta Paster u Parizu 05.05.1995.,pod brojem deponovanja CNCM 1-1572 za upotrebu u lečenju i/ili sprečavanju intestinalnih patoloških stanja zavisnih od butirata i/ili sukcinata.
2. Kompozicija koja obuhvata bakterijski soj Lactobacillus paracasei DG za upotrebu prema zahtevu 1.
3. Kompozicija za upotrebu prema zahtevu 2, pri čemu je pomenuto intestinalno patološko stanje izabrano iz grupe koju čine: dijareja, upala creva, ulcerativni kolitis, gastrična atrofija, crevna divertikuloza, stenoza, opstrukcije i dijabetična neuropatija.
4.Kompozicija za upotrebu prema zahtevu 2 ili 3, pri čemu bakterijski soj Lactobacillus paracasei DG predstavljažzivu ili mrtvu bakteriju, ili bakterijski lizat ili ekstrakt.
5. Kompozicija za upotrebu prema bilo kom od zahteva 2-4 koja obuhvata 15-30 milijardi CFU, poželjno 20-25 milijardi CFU bakterijskog soja Lactobacillus paracasei DG.
6. Kompozicija za upotrebu prema bilo kom od zahteva 2-5 za oralno davanje,poželjno u obliku pilula, kapsula,tableta,granulisanog praška, čvrstih kapsula,granula rastvorljivih u vodi, kesica ili peleta.
7. Kompozicija za upotrebu prerna bilo kom od zahteva 2-5 formulisana u tečnom obliku, poželjno kao sirup ili napitak,ili se dodaje u hranu, poželjno u jogurt,sir ili voćni sok.
8.Kompozicija za upotrebu prema bilo kom od zahteva 2-5 u obliku koji može da dejstvuje topikalno, poželjno u obliku klizme.
9.Kompozicija za upotrebu prema bilo kom od zahteva 2-8 koja dalje obuhvata dijetetska vlakna koja imaju prebiotsku aktivnost,poželjno FOS,inulin ili guar gumu, ili obuhvata druge supstance kao sto su vitamini, elementi u tragovima i/ili enzimi.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001467A ITMI20131467A1 (it) | 2013-09-06 | 2013-09-06 | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
| PCT/IB2014/064285 WO2015033305A1 (en) | 2013-09-06 | 2014-09-05 | Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid |
| EP14790323.1A EP3041489B1 (en) | 2013-09-06 | 2014-09-05 | Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03805B true ME03805B (me) | 2021-04-20 |
Family
ID=49354800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-143A ME03805B (me) | 2013-09-06 | 2014-09-05 | UPOTREBA KOMPOZICIJE KOlA OBUHVATA MIKROORGANIZME ZA POVEĆANJE INTESTINALNE PROIZVODNJE BUTERNE KISELINE, FOLNE KISELINE ILI NIACINA I/ILI SMANJENJE INTESTINALNE PROIZVODNJE ĆILIBARNE KISELINE |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11839634B2 (me) |
| EP (1) | EP3041489B1 (me) |
| JP (1) | JP6651450B2 (me) |
| CN (2) | CN115804798A (me) |
| AU (1) | AU2014316688B2 (me) |
| BR (1) | BR112016005059B1 (me) |
| CA (1) | CA2923392C (me) |
| CY (1) | CY1123127T1 (me) |
| DK (1) | DK3041489T3 (me) |
| EA (1) | EA036534B1 (me) |
| ES (1) | ES2805471T3 (me) |
| HK (1) | HK1224192A1 (me) |
| HR (1) | HRP20201065T1 (me) |
| HU (1) | HUE050146T2 (me) |
| IL (2) | IL244392B (me) |
| IT (1) | ITMI20131467A1 (me) |
| LT (1) | LT3041489T (me) |
| ME (1) | ME03805B (me) |
| MX (1) | MX375509B (me) |
| PL (1) | PL3041489T3 (me) |
| PT (1) | PT3041489T (me) |
| RS (1) | RS60518B1 (me) |
| SG (2) | SG10202001331PA (me) |
| SI (1) | SI3041489T1 (me) |
| SM (1) | SMT202000362T1 (me) |
| WO (1) | WO2015033305A1 (me) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| ITMI20131467A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
| MA39710A (fr) | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| IT201600083376A1 (it) | 2016-08-08 | 2018-02-08 | Sofar Spa | Uso di probiotici per aumentare l’assorbimento proteico |
| ITUA20164188A1 (it) | 2016-06-08 | 2017-12-08 | Sofar Spa | Nuovo uso medico di probiotici |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
| GB201704525D0 (en) | 2017-03-22 | 2017-05-03 | Central Glass Co Ltd | Vehicle glass window with electrical connector soldered by lead-free solder |
| DK3630136T3 (da) * | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| SMT202000695T1 (it) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Limited | Composizioni comprendenti ceppi batterici |
| CA3066189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| SMT202000555T1 (it) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi |
| IT201700101704A1 (it) * | 2017-09-12 | 2019-03-12 | Sofar Spa | Nuovo uso per trattamento delle infezioni da clostridium difficile |
| BR112020010930A2 (pt) * | 2017-12-06 | 2020-11-17 | Lac2biome S.r.l. | composição baseada em probióticos e usos dos mesmos |
| US20200347440A1 (en) * | 2018-01-17 | 2020-11-05 | Consorcio Centro de Investigación Biomédica en Red, M.P. | Targeted interventions directed at reducing the levels of circulating succinate in a subject, and kits and method for determining effectiveness of said interventions |
| CN110358712B (zh) * | 2019-07-26 | 2021-11-09 | 浙江一鸣食品股份有限公司 | 一种乳酸菌组合物及其应用 |
| CN110358714A (zh) * | 2019-08-01 | 2019-10-22 | 浙江一鸣食品股份有限公司 | 一种高产叶酸的乳酸菌组合物 |
| CN110669697B (zh) | 2019-10-31 | 2022-07-15 | 微康益生菌(苏州)股份有限公司 | 一种高产短链脂肪酸的干酪乳杆菌、培养方法及其应用 |
| US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0517363A (ja) | 1991-07-11 | 1993-01-26 | Yakult Honsha Co Ltd | 抗炎症剤及びそれを含有する化粧料 |
| US5716615A (en) | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
| US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
| CN1066926C (zh) | 1996-04-08 | 2001-06-13 | 钟春燕 | 将椰子水发酵制作的食用纤维及其生产方法 |
| US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| CZ9900769A3 (cs) | 1999-03-04 | 2000-10-11 | Petr Ing. Drsc. Hušek | Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem |
| US20020090416A1 (en) | 1999-03-09 | 2002-07-11 | Philip Connolly | Method of enhancing absorption and utilization of protein |
| IT1307850B1 (it) * | 1999-03-15 | 2001-11-19 | Italmed Di Galli Giovanna E Pa | Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio |
| EP1145643A1 (en) | 2000-04-10 | 2001-10-17 | Phillip Connolly | Improved milk protein concentrate |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| RU2182008C1 (ru) | 2000-10-20 | 2002-05-10 | Самойленко Игорь Иннокентьевич | Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии |
| US20030092163A1 (en) * | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| FI20020078A7 (fi) * | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
| US6881419B2 (en) * | 2002-04-09 | 2005-04-19 | William E. Lovett | Vitamin formulation for enhancing bone strength |
| CN1627948A (zh) | 2002-04-24 | 2005-06-15 | 麦迪卡博公司 | 治疗炎症性肠病的组合物和试剂盒 |
| NZ537499A (en) * | 2002-08-06 | 2007-01-26 | Danisco | Use of lactobacillus to produce exopolysaccharides in food and pharmaceutical compositions |
| AU2002951270A0 (en) | 2002-09-06 | 2002-09-19 | Vri Biomedical Ltd | Probiotic Bacterium and Methods of Use |
| WO2005001109A2 (en) | 2003-05-06 | 2005-01-06 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Methods and compositions to detect microbes in fecal samples |
| US20100112088A1 (en) * | 2003-08-29 | 2010-05-06 | Jay Pravda | Materials and methods for treatment of disorders associated with oxidative stress |
| CA2557543A1 (en) | 2004-02-27 | 2005-09-09 | Stichting Laboratorium Voor Infectieziekten | Method for detecting a microorganism in a fecal specimen |
| CA2557834C (en) | 2004-03-04 | 2012-05-22 | E-L Management Corporation | Skin treatment method with lactobacillus extract |
| US20090197249A1 (en) | 2004-11-01 | 2009-08-06 | George Mason University | Compositions and methods for diagnosing colon disorders |
| ES2419205T3 (es) * | 2005-04-06 | 2013-08-19 | Nestec S.A. | Composición para mejorar la regulación de la glicemia y la acción de la insulina, por vía nutritiva |
| FI20051319A7 (fi) | 2005-12-22 | 2007-06-23 | Gut Guide Oy | Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi |
| CN1840206A (zh) | 2006-01-19 | 2006-10-04 | 上海交通大学 | 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法 |
| ES2426038T3 (es) | 2006-02-21 | 2013-10-18 | National University Corporation University Of Toyama | Procedimiento rápido para identificar el microorganismo causante de una enfermedad infecciosa |
| KR101482800B1 (ko) | 2006-02-24 | 2015-01-14 | 큐피가부시키가이샤 | 신규한 저분자량 히알루론산 및/또는 이의 염, 및 이를 이용한 화장료, 의약 조성물 및 식품 조성물 |
| EP2269465A1 (en) * | 2006-05-03 | 2011-01-05 | Probiotical S.p.a. | Compositions comprising Bifidobacterium adolescentis |
| CA2689862A1 (en) | 2006-06-09 | 2007-12-13 | Nutravital Inc. | Probiotic compositions comprising propionibacterium and uses thereof |
| US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
| US20080081035A1 (en) * | 2006-10-03 | 2008-04-03 | National Enzyme Company | Therapeutic protease compositions |
| EP2117354B1 (en) | 2006-12-18 | 2018-08-08 | Advanced BioNutrition Corp. | A dry food product containing live probiotic |
| EP1972208A1 (en) * | 2007-03-16 | 2008-09-24 | Kirin Holdings Kabushiki Kaisha | Composition for improving intestinal microflora |
| US20080241226A1 (en) | 2007-03-27 | 2008-10-02 | Abeln Susan L | Methods and Kits For Administering Probiotics |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| PL2173196T3 (pl) * | 2007-07-06 | 2011-06-30 | Nutricia Nv | Zastosowanie probiotyków i włókien w biegunce |
| US8193155B2 (en) | 2009-02-09 | 2012-06-05 | Elc Management, Llc | Method and compositions for treating skin |
| US20090098088A1 (en) | 2007-10-10 | 2009-04-16 | The Procter & Gamble Company | Methods And Kits For The Treatment Of Diverticular Conditions |
| CN101240315A (zh) | 2008-02-21 | 2008-08-13 | 上海交通大学 | 检测药物防癌效果的非损伤性分子方法 |
| MX2010011995A (es) | 2008-05-01 | 2010-12-02 | Procter & Gamble | Metodos y estuches para el tratamiento de condiciones y trastornos inflamatorios del intestino. |
| WO2010008272A1 (en) | 2008-07-15 | 2010-01-21 | N.V. Nutricia | Treatment of gut motility disorders |
| JP2010161944A (ja) | 2009-01-13 | 2010-07-29 | Syngen Biotech Co Ltd | 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途 |
| BRPI0924902A2 (pt) | 2009-03-05 | 2015-07-07 | Probiotical Spa | Linhagens de bactérias com alta atividade anti-inflamatória |
| WO2010103132A1 (es) | 2009-03-10 | 2010-09-16 | Hero España, S.A. | Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna |
| PL2480255T3 (pl) | 2009-09-23 | 2018-07-31 | Thomas Julius Borody | Terapia przewlekłych zakażeń jelitowych |
| WO2011060123A1 (en) * | 2009-11-12 | 2011-05-19 | Nestec S.A. | Nutritional composition for promoting gut microbiota balance and health |
| AU2010334993B2 (en) * | 2009-12-22 | 2015-07-09 | Probi Ab | Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof |
| US8575130B2 (en) | 2010-01-04 | 2013-11-05 | Holy Stone Healthcare Co., Ltd. | Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease |
| ITUD20100112A1 (it) | 2010-06-09 | 2011-12-10 | Farma Derma S R L | Preparazione per uso vaginale e rettale e relativo procedimento di produzione |
| WO2012135499A1 (en) | 2011-03-31 | 2012-10-04 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
| WO2012154738A1 (en) | 2011-05-09 | 2012-11-15 | The Cleveland Clinic Foundation | Composition and method to improve intestinal health |
| DK2734049T3 (en) | 2011-06-20 | 2018-07-30 | Heinz Co Brands H J Llc | PROBIOTIC COMPOSITIONS AND PROCEDURES |
| GB201219873D0 (en) | 2012-11-05 | 2012-12-19 | Multigerm Uk Entpr Ltd | Diverticulitis treatment |
| CN102919922A (zh) | 2012-11-08 | 2013-02-13 | 黑龙江省轻工科学研究院 | 一种复合益生菌发酵蓝莓果汁粉的制备方法 |
| BR112015020819A2 (pt) | 2013-03-05 | 2017-07-18 | Academisch Ziekenhuis Groningen | uso de faecalibacterium prausnitzii htf-f (dsm 26943) para supressão de inflamação |
| EP3016511B1 (en) * | 2013-07-02 | 2019-10-09 | Austrianova Singapore Pte Ltd. | A method of freeze-drying encapsulated cells, compositions suitable for freezing of encapsulated cells and use of such compositions |
| ITMI20131473A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale |
| ITMI20131467A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
| MA39710A (fr) | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
| AU2015258769A1 (en) | 2014-05-12 | 2016-12-01 | Medlab Ip Pty Ltd | Probiotic compositions and uses thereof for treatment of obesity-related disorders |
| EP2990045B1 (en) | 2014-08-26 | 2016-11-16 | Chr. Hansen A/S | Bifidobacterium animalis subsp. lactis for use in decreasing abdominal pain in a postmenopausal woman |
| IT201600083376A1 (it) | 2016-08-08 | 2018-02-08 | Sofar Spa | Uso di probiotici per aumentare l’assorbimento proteico |
| WO2017195182A1 (en) | 2016-05-13 | 2017-11-16 | Sofar S.P.A. | Use of probiotics for improving protein absorption |
| ITUA20164188A1 (it) | 2016-06-08 | 2017-12-08 | Sofar Spa | Nuovo uso medico di probiotici |
| IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
| IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
| RU2744271C2 (ru) | 2016-12-16 | 2021-03-04 | Компани Жервэ Данон | Пробиотическая композиция, содержащая штаммы Lactobacillus rhamnosus и Lactobacillus paracasei |
| WO2019019961A1 (zh) | 2017-07-26 | 2019-01-31 | 海思科医药集团股份有限公司 | 防治消化道和/或皮肤反应的菌群及其应用 |
| IT201700101704A1 (it) | 2017-09-12 | 2019-03-12 | Sofar Spa | Nuovo uso per trattamento delle infezioni da clostridium difficile |
| BR112020010930A2 (pt) | 2017-12-06 | 2020-11-17 | Lac2biome S.r.l. | composição baseada em probióticos e usos dos mesmos |
| CN108743851A (zh) | 2018-08-09 | 2018-11-06 | 深圳市博奥生物科技有限公司 | 一种复合益生菌粉的制备方法及复合益生菌粉 |
| IT201900016805A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali |
| IT201900016811A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali |
| IT201900016865A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Composizioni a base di ceppi batterici e loro uso come antinfiammatori |
| IT201900016850A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori |
| US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
| IT201900020422A1 (it) | 2019-11-05 | 2021-05-05 | Sofar Spa | Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine |
-
2013
- 2013-09-06 IT IT001467A patent/ITMI20131467A1/it unknown
-
2014
- 2014-09-05 LT LTEP14790323.1T patent/LT3041489T/lt unknown
- 2014-09-05 CN CN202211362855.XA patent/CN115804798A/zh not_active Withdrawn
- 2014-09-05 SG SG10202001331PA patent/SG10202001331PA/en unknown
- 2014-09-05 US US14/916,961 patent/US11839634B2/en active Active
- 2014-09-05 MX MX2016002765A patent/MX375509B/es active IP Right Grant
- 2014-09-05 BR BR112016005059-2A patent/BR112016005059B1/pt active IP Right Grant
- 2014-09-05 SM SM20200362T patent/SMT202000362T1/it unknown
- 2014-09-05 SI SI201431610T patent/SI3041489T1/sl unknown
- 2014-09-05 ME MEP-2020-143A patent/ME03805B/me unknown
- 2014-09-05 HR HRP20201065TT patent/HRP20201065T1/hr unknown
- 2014-09-05 WO PCT/IB2014/064285 patent/WO2015033305A1/en not_active Ceased
- 2014-09-05 PL PL14790323T patent/PL3041489T3/pl unknown
- 2014-09-05 CA CA2923392A patent/CA2923392C/en active Active
- 2014-09-05 EP EP14790323.1A patent/EP3041489B1/en active Active
- 2014-09-05 CN CN201480049296.4A patent/CN105916513A/zh active Pending
- 2014-09-05 AU AU2014316688A patent/AU2014316688B2/en not_active Ceased
- 2014-09-05 DK DK14790323.1T patent/DK3041489T3/da active
- 2014-09-05 EA EA201690464A patent/EA036534B1/ru unknown
- 2014-09-05 RS RS20200806A patent/RS60518B1/sr unknown
- 2014-09-05 PT PT147903231T patent/PT3041489T/pt unknown
- 2014-09-05 HK HK16112483.1A patent/HK1224192A1/zh unknown
- 2014-09-05 HU HUE14790323A patent/HUE050146T2/hu unknown
- 2014-09-05 ES ES14790323T patent/ES2805471T3/es active Active
- 2014-09-05 JP JP2016539667A patent/JP6651450B2/ja not_active Expired - Fee Related
- 2014-09-05 SG SG11201601662SA patent/SG11201601662SA/en unknown
-
2016
- 2016-03-02 IL IL244392A patent/IL244392B/en active IP Right Grant
-
2019
- 2019-09-03 IL IL269107A patent/IL269107B/en active IP Right Grant
-
2020
- 2020-07-13 CY CY20201100642T patent/CY1123127T1/el unknown
-
2023
- 2023-10-24 US US18/493,221 patent/US20240050497A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03805B (me) | UPOTREBA KOMPOZICIJE KOlA OBUHVATA MIKROORGANIZME ZA POVEĆANJE INTESTINALNE PROIZVODNJE BUTERNE KISELINE, FOLNE KISELINE ILI NIACINA I/ILI SMANJENJE INTESTINALNE PROIZVODNJE ĆILIBARNE KISELINE | |
| Burgain et al. | Encapsulation of probiotic living cells: From laboratory scale to industrial applications | |
| Marcial-Coba et al. | Dried date paste as carrier of the proposed probiotic Bacillus coagulans BC4 and viability assessment during storage and simulated gastric passage | |
| CN108883127A (zh) | 用于预防和治疗阴道病的包含乳酸菌的组合物及其用途 | |
| CN103549141A (zh) | 一种猪用中草药复合益生菌饲料添加剂及其制备方法 | |
| Kango et al. | Prebiotics, probiotics and postbiotics: the changing paradigm of functional foods | |
| Hayisama-Ae et al. | A potential synbiotic beverage from fermented red seaweed (Gracilaria fisheri) using Lactobacillus plantarum DW12 | |
| Yang et al. | Effects of Lacidophilin Tablets, Yogurt, and Bifid Triple Viable Capsules on the Gut Microbiota of Mice with Antibiotic‐Associated Diarrhea | |
| CN108771072A (zh) | 一种益生菌组合物及婴幼儿益生菌固体饮料 | |
| US20150313952A1 (en) | Synbiotic composition and use thereof | |
| Casarotti et al. | Effect of different matrices on probiotic resistance to in vitro simulated gastrointestinal conditions | |
| KR20240037981A (ko) | 생리학적으로 허용되는 효모 조성물 및 이의 용도 | |
| Borgonovi et al. | Functional fermented milk with fruit pulp modulates the in vitro intestinal microbiota | |
| US20250114412A1 (en) | Methods of synbiotic treatment to improve health | |
| Li et al. | 2′‐Fucosyllactose promotes Lactobacillus rhamnosus KLDS 8001 to repair LPS‐induced damage in Caco‐2 cells | |
| Yang et al. | Strategies for applying probiotics in the antibiotic management of Clostridioides difficile infection | |
| Li et al. | An isofibrous diet with fiber konjac glucomannan ameliorates Salmonella typhimurium-induced colonic injury by regulating TLR2-NF-κB signaling and intestinal microbiota in mice | |
| Phoem et al. | Eleutherine americana as a growth promotor for infant intestinal microbiota | |
| Peng et al. | Immunomodulatory activities of Lactobacillus rhamnosus ZDY114 and donkey milk in BALB/c mice | |
| Pak et al. | Fermentative capacity of three strains of Lactobacillus using different sources of carbohydrates: in vitro evaluation of synbiotic effects, resistance and tolerance to bile and gastric juices | |
| CN105614853A (zh) | 一种用于提高儿童免疫力的组合物 | |
| Sen et al. | Fruit waste pectin in enhancing the establishment of probiotic bacteria | |
| Sharma et al. | Pre-and probiotics: Using functional foods in the fight against microbial resistance to antibiotics | |
| Bunešová et al. | Effect of rearing systems and diets composition on the survival of probiotic bifidobacteria in the digestive tract of calves | |
| KR102366898B1 (ko) | 천연 추출물과 프로바이오틱스를 포함하여 위와 장 건강에 도움을 주는 조성물 |